Search

Jimmy Van den Eynden

RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cells
Spatial transcriptomics exploration of the primary neuroblastoma microenvironment in archived FFPE samples unveils novel paracrine interactions
Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN
ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition
ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation
11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma
Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib

Published with Hugo Blox Builder — the free, open source website builder that empowers creators.